Pilot Study of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) for Adults With Neurofibromatosis Type 1 (NF1) and Cutaneous Neurofibromas (CNF)

Trial Profile

Pilot Study of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) for Adults With Neurofibromatosis Type 1 (NF1) and Cutaneous Neurofibromas (CNF)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Apr 2018

At a glance

  • Drugs Selumetinib (Primary)
  • Indications Neurofibroma; Neurofibromatoses
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Apr 2018 Planned End Date changed from 31 Dec 2017 to 31 Dec 2018.
    • 10 Apr 2018 Planned End Date changed from 31 Dec 2017 to 31 Dec 2018.
    • 10 Apr 2018 Planned primary completion date changed from 31 Dec 2017 to 31 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top